Concurrent Investment Advisors LLC Grows Stake in CVS Health Corporation $CVS

Key Points

• Concurrent Investment Advisors increased its CVS Health stake by 274% in the second quarter, adding 83,094 shares to hold 113,425 shares worth approximately $11.7 million. Institutional investors and hedge funds collectively own 80.66% of CVS shares.
• Analyst sentiment remains favorable, with 22 analysts rating CVS a Buy and two rating it Hold. The stock has a consensus rating of “Moderate Buy” and an average price target of $106.83.
• CVS Health exceeded quarterly expectations, reporting adjusted earnings of $2.58 per share versus the $1.87 consensus and revenue of $106.1 billion. The company also maintains a quarterly dividend of $0.665, or $2.66 annually, yielding about 2.7%.

Concurrent Investment Advisors LLC grew its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 274.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,425 shares of the pharmacy operator's stock after acquiring an additional 83,094 shares during the period. Concurrent Investment Advisors LLC's holdings in CVS Health were worth $11,734,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in CVS. Caitong International Asset Management Co. Ltd boosted its position in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. acquired a new position in CVS Health in the fourth quarter worth $26,000. Kilter Group LLC acquired a new position in CVS Health in the second quarter valued at approximately $27,000. Sankala Group LLC bought a new position in shares of CVS Health during the 4th quarter valued at about $28,000. Finally, Global Trust Asset Management LLC boosted its stake in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock worth $28,000 after buying an additional 300 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CVS shares. Cantor Fitzgerald raised their price target on shares of CVS Health from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Tuesday, July 7th. Sanford C. Bernstein raised their price objective on CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a research note on Tuesday, May 12th. UBS Group lowered their price target on shares of CVS Health from $126.00 to $118.00 and set a "buy" rating for the company in a research report on Thursday. Weiss Ratings raised shares of CVS Health from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 5th. Finally, Argus upped their price target on shares of CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $106.83.

CVS Health Trading Down 0.4%

NYSE:CVS opened at $96.80 on Friday. The stock has a fifty day moving average price of $100.79 and a 200 day moving average price of $90.14. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market cap of $123.80 billion, a PE ratio of 25.61, a price-to-earnings-growth ratio of 0.95 and a beta of 0.59. CVS Health Corporation has a 12-month low of $69.51 and a 12-month high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the company earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's dividend payout ratio (DPR) is presently 70.37%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source